Halbach, Sebastian Hu, Zehan Gretzmeier, Christine Ellermann, Julia Wöhrle, Franziska Dengjel, Jörn Brummer, Tilman Additional file 4: Table S1. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells Anti-GAB2 IP of Imatinib vs DMSO treated cells. Experiment 1 and 2 are averages of two replicates each. SILAC ratios are normalized to GAB2 and log2 transformed. Significant affected proteins are determined using Significance A (MaxQuant, p < 0.05, BH corrected). Proteins are shortlisted if minimally one IP exhibited a significant regulation and the other IP showed the same trend (see Additional file 2: Figure S2). PEP: posterior error probability. (XLSX 231 kb) Chronic myeloid leukemia;CML;TKI resistance;Imatinib;Sorafenib;Axitinib;Ponatinib;Gab2;Hyperactive Lyn;Bcr-Abl 2016-02-24
    https://springernature.figshare.com/articles/dataset/Additional_file_4_Table_S1_of_Axitinib_and_sorafenib_are_potent_in_tyrosine_kinase_inhibitor_resistant_chronic_myeloid_leukemia_cells/4377602
10.6084/m9.figshare.c.3615767_D7.v1